{"slug":"car-t","tag":"car-t","variants":["car-t"],"description":"No description yet","count":13,"kinds":{"person":13},"related":[{"slug":"cell-therapy","tag":"cell-therapy","shared":7},{"slug":"lymphoma","tag":"lymphoma","shared":5},{"slug":"myeloma","tag":"myeloma","shared":3},{"slug":"paediatric","tag":"paediatric","shared":3},{"slug":"bone-disease","tag":"bone-disease","shared":1},{"slug":"cancer-neuroscience","tag":"cancer-neuroscience","shared":1},{"slug":"community-research","tag":"community-research","shared":1},{"slug":"engineering","tag":"engineering","shared":1},{"slug":"genomics","tag":"genomics","shared":1},{"slug":"glioma","tag":"glioma","shared":1},{"slug":"mantle-cell","tag":"mantle-cell","shared":1},{"slug":"second-line","tag":"second-line","shared":1}],"records":[{"id":"michelle-monje","kind":"person","name":"Michelle Monje","route":"/people/michelle-monje/","tldr":"Founded cancer neuroscience and led the GD2 CAR-T trial that produced the first regressions of diffuse midline glioma."},{"id":"sattva-neelapu","kind":"person","name":"Sattva S. Neelapu","route":"/people/sattva-neelapu/","tldr":"Led ZUMA-1, the trial that made axicabtagene ciloleucel the first CAR-T therapy approved for lymphoma."},{"id":"stephen-schuster","kind":"person","name":"Stephen J. Schuster","route":"/people/stephen-schuster/","tldr":"Led JULIET, which brought tisagenlecleucel, the first CAR-T, to adults with relapsed large B-cell lymphoma."},{"id":"jason-westin","kind":"person","name":"Jason R. Westin","route":"/people/jason-westin/","tldr":"Led the ZUMA-7 overall survival analysis that made CAR-T the standard second-line therapy for early-relapsing lymphoma."},{"id":"michael-wang","kind":"person","name":"Michael L. Wang","route":"/people/michael-wang/","tldr":"Led the ibrutinib and brexucabtagene autoleucel trials that transformed mantle cell lymphoma treatment."},{"id":"nikhil-munshi","kind":"person","name":"Nikhil C. Munshi","route":"/people/nikhil-munshi/","tldr":"Led KarMMa, which brought idecabtagene vicleucel, the first CAR-T for myeloma, to approval."},{"id":"jesus-berdeja","kind":"person","name":"Jesús G. Berdeja","route":"/people/jesus-berdeja/","tldr":"Led CARTITUDE-1, the trial that brought ciltacabtagene autoleucel, the most active myeloma CAR-T, to approval."},{"id":"noopur-raje","kind":"person","name":"Noopur Raje","route":"/people/noopur-raje/","tldr":"Led the first-in-human trial of BCMA CAR-T (bb2121) in myeloma and studies of bone disease treatment."},{"id":"michel-sadelain","kind":"person","name":"Michel Sadelain","route":"/people/michel-sadelain/","tldr":"Designed the second-generation CAR with a CD28 costimulatory domain that made CAR-T therapy work."},{"id":"stephan-grupp","kind":"person","name":"Stephan A. Grupp","route":"/people/stephan-grupp/","tldr":"Treated the first child with CAR-T cells and led ELIANA, the trial behind the first CAR-T approval."},{"id":"marcela-maus","kind":"person","name":"Marcela V. Maus","route":"/people/marcela-maus/","tldr":"Cell therapy engineer whose CAR-TEAM cells produced rapid regressions of recurrent glioblastoma."},{"id":"robbie-majzner","kind":"person","name":"Robbie G. Majzner","route":"/people/robbie-majzner/","tldr":"Led the GD2 CAR-T trial in diffuse midline glioma and defined antigen density as a barrier to CAR-T in solid tumours."},{"id":"caron-jacobson","kind":"person","name":"Caron A. Jacobson","route":"/people/caron-jacobson/","tldr":"Boston lymphoma doctor who led ZUMA-5, the trial that brought the CAR-T therapy axicabtagene ciloleucel to relapsed follicular lymphoma."}]}